Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. develops and commercializes surgical robotic technologies centered on the SSi Mantra Surgical Robotic System, a modular multi-arm platform used across multiple surgical specialties. Company news commonly covers SSi Mantra procedure milestones, global system installations, telesurgery demonstrations, regulatory approvals in international markets, and financial results tied to installations, procedures and revenue.
Updates also address the company’s surgical robotics ecosystem, including the SSi MantrAsana tele-surgeon console, the MantraM mobile robotic telesurgery unit, SSi Mudra instrumentation, and development-stage concepts such as SSi Vimana Aero, SSi Avtara and SSi Operion. Capital actions, Nasdaq trading status and company-hosted robotic surgery conferences are additional recurring themes.
SS Innovations (Nasdaq: SSII) reported record Q1 2026 revenue of $11.1 million, up 116.8% year over year. Gross margin rose to 48.0% and gross profit reached $5.3 million. Net loss narrowed to $3.6 million ($0.02/share). The SSi Mantra installed base grew to 194 systems across eleven countries with 9,744 cumulative surgeries. Cash and cash equivalents were $16.0 million with no long-term debt. The company raised $18.6 million in a March 2026 private placement and gained new regulatory approvals for SSi Mantra in Sri Lanka, Kenya, Indonesia, and the Philippines.
SS Innovations (Nasdaq: SSII) announced a successful long-distance cross-border telesurgery on May 2, 2026, connecting a surgeon in Perth, Australia to a patient in Indore, India, spanning more than 4,500 miles. The procedure used the SSi Mantra surgical robot and the portable SSi MantrAsana tele-surgeon console.
According to the company, the MantrAsana supports ultra-low latency connectivity, high-definition visualization, and precise instrument control; SS Innovations says the SSi Mantra platform has been used in more than 170 telesurgeries to date.
SS Innovations (Nasdaq: SSII) announced that more than 10,500 cumulative surgeries have been performed using its SSi Mantra surgical robotic system as of April 30, 2026. The tally includes >500 cardiac procedures, 170 telesurgeries, 125 pediatric surgeries, ~2,100 trained physicians, and an installed base of >200 systems across 11 countries.
The milestone highlights multi-specialty adoption and training scale since the SSi Mantra commercial launch in August 2022.
SS Innovations (Nasdaq: SSII) unveiled multiple surgical robotic concepts at SMRSC 2026 on April 23, 2026, in New Delhi, including the SSi Vimana Aero drone-delivered surgical system, SSi Avtara humanoid platform, SSi Operion mobile operating room, and single-arm endoscopy/ultrasound assist carts.
SMRSC 2026 drew over 1,600 onsite and 1,800 virtual attendees; the company demonstrated the SSi Mantra with 10 live telesurgeries and 13 live robotic surgeries. Single-arm carts are in early clinical validation in India.
SS Innovations (Nasdaq: SSII) will host the Global Multi-Specialty Robotic Surgery Conference, SMRSC 2026, in New Delhi, India from April 9-11, 2026. The event features live telesurgeries, the SSi MantrAsana tele surgeon console, the SSi Vimana Aero drone trauma system, Project Operion and the MantraM mobile unit.
The conference aims to showcase multispecialty robotic demos, training, telesurgery protocols and innovations that support decentralized access to robotic surgical care.
SS Innovations (Nasdaq: SSII) received regulatory approvals for the SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya.
The approvals were granted by INVIMA (Colombia, Nov 2025), DGPA&DC (Oman, Nov 2025), NMRA (Sri Lanka, Jan 2026) and PPB (Kenya, Jan 2026). The SSi Mantra now has approval in eleven countries and a cumulative installed base of 168 systems with 7,885 surgeries through Dec 31, 2025.
SS Innovations (Nasdaq: SSII) announced regulatory approval for telesurgeries using its SSi Mantra surgical robotic system in Indonesia and the Philippines on March 18, 2026. The company also reported surpassing 150 cumulative telesurgeries, with high‑volume sessions in India demonstrating multi‑case capability.
Recent operational highlights include 18 inter‑hospital telesurgeries on February 14, 2026, and a 24‑case telesurgery marathon on December 23, 2025, using the portable SSi MantraAsana console.
SS Innovations (Nasdaq: SSII) reported strong 2025 growth with revenue up 105.7% to $42.5M and gross margin expanding to 46.0%. SSi Mantra installations rose to 103 (+119.1%) and cumulative surgeries reached 7,885. The company completed a private placement raising ~$18.6M and had $3.2M cash as of December 31, 2025.
Fourth-quarter revenue was $14.5M (+79.1%) with 40 installations. Full-year net loss improved to $12.1M from $19.2M in 2024. Management expects FDA 510(k) review by mid-2026 and continued global expansion.
SS Innovations (NASDAQ: SSII) completed a private placement on March 6, 2026, raising approximately $18.6 million in gross proceeds through the sale of 5,774,839 common shares.
The offering included insider purchases by the CEO, vice-chairman and a director, a $2.5 million investor that triggered a 7% cash commission and five-year warrants, and participation led by Manipal Global Health Services. Proceeds will fund working capital and global expansion, including planned U.S. FDA 510(k) review and EU CE marking efforts for the SSi Mantra surgical robotic system.
SS Innovations (Nasdaq: SSII) reported preliminary unaudited results for Q4 and full-year 2025 showing significant unit and revenue growth. Q4 2025 revenue is estimated at $15.0 million, up 85% from $8.1 million a year earlier, with 37 SSi Mantra installations in the quarter, up 68% year-over-year. Full-year 2025 revenue is estimated at $43.0 million, up 108% from $20.6 million in 2024, and 103 SSi Mantra installations for the year, up 119%.
The cumulative installed base reached 168 systems at year-end 2025. Management said FDA 510(k) review and EU CE marking are anticipated in the first half of 2026. Results are preliminary, unaudited and subject to final quarter-end procedures and change.